有望打破双巨头垄断？“减肥药新星”Viking股价年内暴涨247%

格隆汇07-26

隔夜，Viking Therapeutics股价暴涨28%，报64.68美元，总市值71.66亿美元。今年以来，Viking Therapeutics已累计上涨247.56%。消息面上，Viking Therapeutics的减肥药开发进程加快。研发进程加快此前，Viking Therapeutics曾表示，在2月底的一项二期研究的积极结果后，预计将开始减肥药VK2735的中期试验。不过，在周三的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2454355980?lang=zh_CN&edition=full","thumbnail":"https://img3.gelonghui.com/cf5c3-80d27774-ed63-490a-977d-1ea8fc925c87.jpg?guru_height=852&guru_width=1280","is_english":false,"pubTime":"2024-07-26 09:25","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2454355980","market":"us","top_or_hot":-1,"title":"有望打破双巨头垄断？“减肥药新星”Viking股价年内暴涨247%","media":"格隆汇","content":"<div>\n<p>隔夜，Viking Therapeutics股价暴涨28%，报64.68美元，总市值71.66亿美元。今年以来，Viking Therapeutics已累计上涨247.56%。消息面上，Viking Therapeutics的减肥药开发进程加快。研发进程加快此前，Viking Therapeutics曾表示，在2月底的一项二期研究的积极结果后，预计将开始减肥药VK2735的中期试验。不过，在周三的...</p>\n\n<a href=\"https://www.gelonghui.com/p/880989\">网页链接</a>\n\n</div>\n","source":"gelonghui_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>有望打破双巨头垄断？“减肥药新星”Viking股价年内暴涨247%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n有望打破双巨头垄断？“减肥药新星”Viking股价年内暴涨247%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-26 09:25 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/p/880989><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>隔夜，Viking Therapeutics股价暴涨28%，报64.68美元，总市值71.66亿美元。今年以来，Viking Therapeutics已累计上涨247.56%。消息面上，Viking Therapeutics的减肥药开发进程加快。研发进程加快此前，Viking Therapeutics曾表示，在2月底的一项二期研究的积极结果后，预计将开始减肥药VK2735的中期试验。不过，在周三的...</p>\n\n<a href=\"https://www.gelonghui.com/p/880989\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJJMRZ35.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","start_time":0,"source_url":"https://www.gelonghui.com/p/880989","article_id":"2454355980","we_media_id":null,"thumbnails":["https://img3.gelonghui.com/cf5c3-80d27774-ed63-490a-977d-1ea8fc925c87.jpg?guru_height=852&guru_width=1280"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2454355980","pubTimestamp":1721957152,"sourceInfo":{"source_id":"gelonghui_highlight","name":"格隆汇"},"weMediaInfo":null,"summary":"礼来市值蒸发1200亿美元","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LLY":"礼来","BK4534":"瑞士信贷持仓","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0882574139.USD":"富达环球消费行业基金A ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4007":"制药","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","VKTX":"Viking Therapeutics, Inc.","BK4516":"特朗普概念","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","BK4588":"碎股","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","NVO":"诺和诺德","LU0882574055.USD":"富达全球健康医疗A ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC"},"translate_title":"Expected to break the monopoly of the two giants? \"Rising Star of Weight Loss Pills\" Viking's Stock Price Soared 247% During the Year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":1,"NVO":0.7,"LLY":0.7},"content_text":"隔夜，Viking Therapeutics股价暴涨28%，报64.68美元，总市值71.66亿美元。今年以来，Viking Therapeutics已累计上涨247.56%。消息面上，Viking Therapeutics的减肥药开发进程加快。研发进程加快此前，Viking Therapeutics曾表示，在2月底的一项二期研究的积极结果后，预计将开始减肥药VK2735的中期试验。不过，在周三的电话财报会议上，公司首席执行官Brian Lian表示，在收到美国食品和药物管理局的书面反馈后，公司已决定将直接进入第三阶段试验。Lian透露，正在准备四季度与FDA会面，讨论第三阶段试验的设计和时间安排，并计划随后开始研究。对此，BTIG的分析师Justin Zelin在周三的一份报告中表示，这一决定可能会将Viking Therapeutics减肥药的开发时间表缩短一年。 Zelin表示，分析师目前预计该药物将于2029年上市。Lian还透露，将在未来的研究中测试VK2735作为每月注射剂使用。这或将使其成为比礼来的Zepbound、诺和诺德Wegovy更为方便的选择，Zepbound和Wegovy均需要每周使用一次。数据显示，在第二阶段试验中，每周注射Viking Therapeutics注射剂的患者在13周后体重减轻了14.7%，与安慰剂相比减轻了13.1%。 此外，Viking Therapeutics还正在开发VK2735的口服版本，将从第四季度开始进入中期试验。在早期试验中，与安慰剂相比，该口服版本可使体重减轻3.3%。礼来市值蒸发1200亿美元除了Viking Therapeutics，减肥药领域的新星不断。此前，瑞士制药巨头罗氏公司也表示，继上周实验性减肥药取得可喜成果后，该公司计划加速其减肥药的开发。在此背景下，礼来、诺和诺德的主导地位受到挑战。礼来的股价周四收盘下跌4.5%，创下5月以来的最低水平，过去8个交易日累计下跌14%，市值蒸发了1200亿美元。不过，礼来年内的涨幅仍为41.36%。诺和诺德周四下跌近3%，年内累计上涨24.49%。瑞穗的分析师Jared Holz表示：“我们的假设是，减肥药领域不会永远是双巨头垄断。我预计，竞争性产品试验带来的这种相当激烈的反应会随着时间的推移而减少。”Holz认为，当前的市场轮动，即交易员正在撤离表现优异的大型股，是礼来股价大跌的另一个重要因素。他补充称，如果股价保持在这个较低水平附近，8月8日发布二季度财报后，礼来可能会反弹。他表示：“如果所有迹象都表明基本面非常强劲，那么我认为该股将会复苏。”","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2454355980"}